Mirati Therapeutics Inc (MRTX) 19.10 $MRTX
Launch of Additional First- and Second-Line Options Will Substantially Expand the Treatment Landscape for Myelodysplastic Syndromes Through 2023
PR Newswire - Thu Apr 03, 10:00AM CDT
Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to clinical trial data and expert opinion, treatment options for MDS will expand significantly over the next decade with the launches of as many as five novel therapies: Cyclacel's sapacitabine, Mirati Therapeutics' mocetinostat, Celgene's oral azacitidine, Onconova's oral rigosertib and Acceleron/Celgene's sotatercept, as well as a label extension for GlaxoSmithKline's Revolade/Promacta.
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 24, 2:40PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
William R. Ringo Joins Mirati Board of Directors
PR Newswire - Thu Mar 20, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran William Ringo has joined its board of directors.
Mirati Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 17, 3:01PM CDT
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today reported financial results for the fourth quarter and year ended December 31, 2013 and provided a corporate update.
2 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 25, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Mirati Therapeutics to Present at the 2014 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 05, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13 at 1:00 PM Eastern Time in New York.
Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
PR Newswire - Mon Dec 09, 9:10AM CST
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes (MDS) patients treated with mocetinostat in combination with azacitidine. Separately, Mirati announced that it has dosed the first patients in its Phase 2 dose confirmation trial of mocetinostat in combination with azacitidine for the treatment of MDS.
Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Mon Dec 02, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 10:30 AM Eastern Time in New York.
Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Fri Nov 22, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 4:00 PM Eastern Time in New York.
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today reported financial results for the third quarter and nine months ended September 30, 2013.
Mirati Therapeutics to Present Data on Phase 1/2 Trial of Mocetinostat at the 55th American Society of Hematology Annual Meeting
PR Newswire - Fri Nov 08, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in myelodysplastic syndromes (MDS) at the 55th American Society of Hematology Annual Meeting taking place December 7-10 in New Orleans. Data to be presented demonstrates promising clinical responses to the combination of mocetinostat, a novel spectrum selective HDAC inhibitor, with azacitidine (marketed as Vidaza® by Celgene) in patients with MDS. The abstract is currently available online at https://ash.confex.com/ash/2013/webprogram/Paper64121.html.
5 Stocks Insiders Love Right Now
at The Street - Wed Oct 30, 11:45AM CDT
Mirati Therapeutics Prices Public Offering Of Common Stock
PR Newswire - Wed Oct 23, 7:13PM CDT
Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $17.50 per share. The gross proceeds from this offering to Mirati are expected to be approximately $56.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an aggregate of 487,500 additional shares of common stock. The offering is expected to close on or about October 29, 2013, subject to customary closing conditions. Mirati expects to use net proceeds of this offering for research and development expenses, working capital, potential future licensing or partnership transactions and for other general corporate expenses.
Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of Directors
Marketwire - Wed Sep 04, 5:31AM CDT
Mirati Therapeutics (NASDAQ: MRTX) today announced the appointment of Isan Chen, M.D., as chief medical and development officer as well as the appointment of Craig Johnson to its board of directors and as the chairman of the audit committee.
Mirati Therapeutics Reports Second Quarter 2013 Financial Results
Marketwire - Mon Aug 12, 5:31AM CDT
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today reported financial results for the second quarter and first six months ended June 30, 2013.
Mirati Therapeutics to Voluntarily Delist from TSX
Marketwire - Fri Jul 19, 3:22PM CDT
Mirati Therapeutics Inc. (TSX: MYG)(NASDAQ: MRTX) ("Mirati Therapeutics" today announced that, consistent with its previously disclosed plans, it has applied to the Toronto Stock Exchange ("TSX" to voluntarily delist from trading its shares of common stock. Effective at market close on July 26, 2013, Mirati's common stock will no longer be traded through the facilities of the TSX. Mirati's shares of common stock are currently traded, and will continue to be traded, on the NASDAQ Capital Market ("NASDAQ" , under the ticker symbol "MRTX".
Launch of Additional First- and Second-Line Options Will Substantially Expand the Treatment Landscape for Myelodysplastic Syndromes Through 2023
PR Newswire - Thu Apr 03, 10:00AM CDT
Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to clinical trial data and expert opinion, treatment options for MDS will expand significantly over the next decade with the launches of as many as five novel therapies: Cyclacel's sapacitabine, Mirati Therapeutics' mocetinostat, Celgene's oral azacitidine, Onconova's oral rigosertib and Acceleron/Celgene's sotatercept, as well as a label extension for GlaxoSmithKline's Revolade/Promacta.
Nasdaq stocks posting largest percentage decreases
AP - Mon Mar 24, 2:40PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
William R. Ringo Joins Mirati Board of Directors
PR Newswire - Thu Mar 20, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran William Ringo has joined its board of directors.
Mirati Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 17, 3:01PM CDT
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today reported financial results for the fourth quarter and year ended December 31, 2013 and provided a corporate update. 2 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 25, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.
Mirati Therapeutics to Present at the 2014 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 05, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13 at 1:00 PM Eastern Time in New York.
Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
PR Newswire - Mon Dec 09, 9:10AM CST
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes (MDS) patients treated with mocetinostat in combination with azacitidine. Separately, Mirati announced that it has dosed the first patients in its Phase 2 dose confirmation trial of mocetinostat in combination with azacitidine for the treatment of MDS. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Mon Dec 02, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 10:30 AM Eastern Time in New York.
Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Fri Nov 22, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 4:00 PM Eastern Time in New York.
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today reported financial results for the third quarter and nine months ended September 30, 2013. Mirati Therapeutics to Present Data on Phase 1/2 Trial of Mocetinostat at the 55th American Society of Hematology Annual Meeting
PR Newswire - Fri Nov 08, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in myelodysplastic syndromes (MDS) at the 55th American Society of Hematology Annual Meeting taking place December 7-10 in New Orleans. Data to be presented demonstrates promising clinical responses to the combination of mocetinostat, a novel spectrum selective HDAC inhibitor, with azacitidine (marketed as Vidaza® by Celgene) in patients with MDS. The abstract is currently available online at https://ash.confex.com/ash/2013/webprogram/Paper64121.html. 5 Stocks Insiders Love Right Now
at The Street - Wed Oct 30, 11:45AM CDT
Mirati Therapeutics Prices Public Offering Of Common Stock
PR Newswire - Wed Oct 23, 7:13PM CDT
Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $17.50 per share. The gross proceeds from this offering to Mirati are expected to be approximately $56.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an aggregate of 487,500 additional shares of common stock. The offering is expected to close on or about October 29, 2013, subject to customary closing conditions. Mirati expects to use net proceeds of this offering for research and development expenses, working capital, potential future licensing or partnership transactions and for other general corporate expenses.
Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of Directors
Marketwire - Wed Sep 04, 5:31AM CDT
Mirati Therapeutics (NASDAQ: MRTX) today announced the appointment of Isan Chen, M.D., as chief medical and development officer as well as the appointment of Craig Johnson to its board of directors and as the chairman of the audit committee.
Mirati Therapeutics Reports Second Quarter 2013 Financial Results
Marketwire - Mon Aug 12, 5:31AM CDT
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today reported financial results for the second quarter and first six months ended June 30, 2013. Mirati Therapeutics to Voluntarily Delist from TSX
Marketwire - Fri Jul 19, 3:22PM CDT
Mirati Therapeutics Inc. (TSX: MYG)(NASDAQ: MRTX) ("Mirati Therapeutics"
today announced that, consistent with its previously disclosed plans, it has applied to the Toronto Stock Exchange ("TSX" to voluntarily delist from trading its shares of common stock. Effective at market close on July 26, 2013, Mirati's common stock will no longer be traded through the facilities of the TSX. Mirati's shares of common stock are currently traded, and will continue to be traded, on the NASDAQ Capital Market ("NASDAQ" , under the ticker symbol "MRTX". 
